title: Rapid fatal pulmonary complications in a Chinese patient after bortezomib treatment for ALK-negative anaplastic large-cell lymphoma.
abstract: Bortezomib, a reversible proteasome inhibitor, is used for the treatment of hematologic malignancies. Common adverse events with bortezomib include gastrointestinal symptoms, thrombocytopenia, and neuropathy, whereas severe pulmonary complications have been rarely described. Herein, we present a case of rapid fatal pulmonary complications in a patient with ALK-negative anaplastic large-cell lymphoma after receiving a treatment with bortezomib.
authors.affiliation: Department of Hematology, Wuxi People's Hospital, Nanjing Medical University, Wuxi, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Zhou
authors.forename: Chao
authors.initials: C
authors.lastname: Sun
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.forename: Jingjue
authors.initials: J
authors.lastname: Mao
authors.forename: Hongfeng
authors.initials: H
authors.lastname: Guo
mesh_terms: D000368:Aged; D044466:Asian People; D001897:Boronic Acids / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000069286:Bortezomib; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D017809:Fatal Outcome; D019337:Hematologic Neoplasms / Q000139:chemically induced / Q000201:enzymology; D006801:Humans; D008168:Lung / Q000201:enzymology / Q000378:metabolism; D016403:Lymphoma, Large B-Cell, Diffuse / Q000139:chemically induced / Q000188:drug therapy / Q000201:enzymology; D017728:Lymphoma, Large-Cell, Anaplastic / Q000139:chemically induced / Q000201:enzymology; D008297:Male; D011719:Pyrazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D001897:Boronic Acids; D004791:Enzyme Inhibitors; D011719:Pyrazines; D000069286:Bortezomib